MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

Search

CRISPR Therapeutics AG

Открыт

СекторЗдравоохранение

71.27 4.17

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

67.28

Макс.

73.7

Ключевые показатели

By Trading Economics

Доход

-73M

-209M

Продажи

27K

892K

Рентабельность продаж

-23,379.933

Сотрудники

393

EBITDA

-59M

-203M

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

-4.19% downside

Дивиденды

By Dow Jones

Следующий отчет о доходах

4 нояб. 2025 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

653M

5.8B

Предыдущая цена открытия

67.1

Предыдущая цена закрытия

71.27

Новостные настроения

By Acuity

50%

50%

149 / 371 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Very Strong Bearish Evidence

CRISPR Therapeutics AG График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

2 окт. 2025 г., 23:30 UTC

Популярные акции

Stocks to Watch: Rumble, Applied Materials, American Outdoor Brands

2 окт. 2025 г., 21:21 UTC

Отчет

Applied Materials Expects New Export Rule to Hit 2026 Revenue by $600 Million

3 окт. 2025 г., 00:00 UTC

Приобретения, слияния, поглощения

Warren Buffett's Berkshire Comes to the Aid of Occidental Petroleum -- Again -- WSJ

2 окт. 2025 г., 23:40 UTC

Обсуждения рынка

Gold Edges Higher, Aided by Risks U.S. Shutdown May Weaken Economy -- Market Talk

2 окт. 2025 г., 23:39 UTC

Обсуждения рынка

Japanese Stocks May Edge Higher, Tracking Wall Street Gains -- Market Talk

2 окт. 2025 г., 23:29 UTC

Приобретения, слияния, поглощения

Vistra: Transaction Remains on Track to Close This Qtr or 1Q 2026 >VST

2 окт. 2025 г., 23:29 UTC

Приобретения, слияния, поглощения

Vistra: Received Regulatory Approval From FERC for Acquisition of Certain Subsidiaries Owning Seven Natural-Gas Generation Facilities From Lotus Infrastructure Partners >VST

2 окт. 2025 г., 23:29 UTC

Приобретения, слияния, поглощения

Vistra: Next Step in Acquisition of Gas Generation Fleet With Approval From Federal Energy Regulatory Commission

2 окт. 2025 г., 23:00 UTC

Обсуждения рынка

Warehouse Needs Time to Restore Credibility With Investors -- Market Talk

2 окт. 2025 г., 22:54 UTC

Обсуждения рынка
Приобретения, слияния, поглощения

Scales's JV Buyout Lauded by Bull -- Market Talk

2 окт. 2025 г., 22:54 UTC

Обсуждения рынка
Приобретения, слияния, поглощения

Global Forex and Fixed Income Roundup: Market Talk

2 окт. 2025 г., 22:46 UTC

Обсуждения рынка

Synlait Milk Loses Bear Following Sale of North Island Assets -- Market Talk

2 окт. 2025 г., 22:46 UTC

Обсуждения рынка

Global Equities Roundup: Market Talk

2 окт. 2025 г., 21:17 UTC

Приобретения, слияния, поглощения

Buffett Scores Win in Berkshire's Deal for Occidental Chemicals Unit -- Barrons.com

2 окт. 2025 г., 20:50 UTC

Обсуждения рынка
Приобретения, слияния, поглощения

Energy & Utilities Roundup: Market Talk

2 окт. 2025 г., 20:50 UTC

Обсуждения рынка

Basic Materials Roundup: Market Talk

2 окт. 2025 г., 20:49 UTC

Приобретения, слияния, поглощения

OpenAI's Latest Funding Deal Returns Focus to AI Economy, Lifting U.S. Stocks -- WSJ

2 окт. 2025 г., 20:00 UTC

Приобретения, слияния, поглощения

Legrand Signs Definitive Agreement To Acquire Avtron Power Solutions, A Global Provider Of Load Banks & Power Quality Solutions >LR.FR

2 окт. 2025 г., 19:20 UTC

Обсуждения рынка

Natural Gas Snaps Winning Streak Despite Small Inventory Rise -- Market Talk

2 окт. 2025 г., 19:10 UTC

Обсуждения рынка

Bank of Canada to Publish Inflation Dashboard in 2026 -- Market Talk

2 окт. 2025 г., 19:04 UTC

Обсуждения рынка

Oil Futures Extend Losses as Markets Brace for Higher Output -- Market Talk

2 окт. 2025 г., 18:46 UTC

Приобретения, слияния, поглощения

Honeywell: Transaction Expected to Improve Annual Free Cash Flow by More Than $100 M Over Next Several Years and Then Decrease Over Time >HON

2 окт. 2025 г., 18:46 UTC

Приобретения, слияния, поглощения

Honeywell: Loss Will Be Excluded From Adjusted EPS >HON

2 окт. 2025 г., 18:46 UTC

Приобретения, слияния, поглощения

Honeywell: Estimated Impact of Divestiture Will Be One-Time Loss of About $115 M >HON

2 окт. 2025 г., 18:45 UTC

Приобретения, слияния, поглощения

Honeywell Will Have No Further Fincl Exposure to the Transferred Liabilities >HON

2 окт. 2025 г., 18:45 UTC

Приобретения, слияния, поглощения

Honeywell Utilized Portion of Cash From Resideo Indemnification and Reimbursement Agreement Termination to Fund Delticus Transaction >HON

2 окт. 2025 г., 18:44 UTC

Приобретения, слияния, поглощения

Honeywell: Delticus Assumed Full Responsibility for Administering and Resolving All Current and Future Asbestos-Related Claims >HON

2 окт. 2025 г., 18:44 UTC

Приобретения, слияния, поглощения

Honeywell and Delticus Contributed About $1.68 B in Cash, as Well as Certain Insurance Assets Related to Legacy Asbestos Liabilities >HON

2 окт. 2025 г., 18:44 UTC

Приобретения, слияния, поглощения

Honeywell: Transaction Strengthens Annual Free Cash Flow Generation >HON

2 окт. 2025 г., 18:43 UTC

Приобретения, слияния, поглощения

Honeywell Divested All Legacy Bendix Asbestos Liabilities, as Well as Certain Non-Bendix Asbestos Liabilities, to Delticus >HON

Сравнение c конкурентами

Изменение цены

CRISPR Therapeutics AG Прогноз

Целевая цена

By TipRanks

-4.19% падение

Прогноз на 12 месяцев

Средняя 69.77 USD  -4.19%

Максимум 100 USD

Минимум 40 USD

Основано на мнении 15 аналитиков Wall Street, спрогнозировавших целевые цены для CRISPR Therapeutics AG на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

15 ratings

10

Покупка

5

Удержание

0

Продажа

Техническая оценка

By Trading Central

33.5 / 38.27Поддержка и Сопротивление

Краткосрочная

Very Strong Bearish Evidence

Среднесрочная

Strong Bearish Evidence

Долгосрочная

Bearish Evidence

Настроения

By Acuity

149 / 371Рейтинг в Здравоохранение

Новостные настроения

Neutral

Волатильность

Ниже среднего

Объем новостей (RCV)

Выше среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании CRISPR Therapeutics AG

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease, and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmunune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and VCTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
help-icon Live chat